Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression
- PMID: 7855002
- DOI: 10.1002/pros.2990260205
Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression
Abstract
Prostatic carcinomas vary in their biological potential, even when stratified by grade and stage. Measurement of cellular proliferation by various methods has been shown to correlate with outcome for several human cancers, including prostatic carcinoma. Uptake of bromodeoxyuridine (BrdUrd), a thymidine analogue, has been accepted as a measure of cellular proliferative rate. However, the technique is somewhat complex, requiring incubation with fresh tissue. We compared cellular proliferation as measured by BrdUrd uptake with two more simple immunohistochemical methods in 44 prostatic adenocarcinoma specimens and correlated the results with standard clinical parameters. The tissue was obtained via needle biopsy, channel transurethral resection, and radical prostatectomy. Specimens were incubated in vitro with BrdUrd and then fixed and paraffin embedded. Sections were immunohistochemically stained with antibodies to BrdUrd, proliferating cell nuclear antigen (PCNA), and Ki-67. At least 1,000 cells were scored, and a labeling index (LI) was calculated (number of positive cells/total number of cells). The mean LI determined by all three indices was low (BrdUrd = 3.0, PCNA = 7.0, Ki-67 = 3.4), consistent with the knowledge that prostatic tumors grow slowly. In 36 patients who had not been treated at the time of analysis, the LI as determined by all three methods correlated well with clinical stage and pathological grade. Furthermore, the LIs discriminated between those with tumor confined to the prostate and those with extension to the seminal vesicles, lymph nodes, or bone (P = 0.003, 0.004, 0.008 for BrdUrd, PCNA, and Ki-67, respectively). The LIs for PCNA and Ki-67 correlated well with that for BrdUrd (r = 0.84; r = 0.85), while the LIs for Ki-67 and PCNA correlated slightly less well with each other (r = 0.78). PCNA and Ki-67 expression appear to reflect essentially the same biological process as BrdUrd uptake. Either can substitute for BrdUrd as a measure of cellular proliferation, and Ki-67 seems to offer the fewest technical problems.
Similar articles
-
Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression.J Urol. 1993 Feb;149(2):403-7. doi: 10.1016/s0022-5347(17)36104-9. J Urol. 1993. PMID: 8093910
-
Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.Acta Neuropathol. 1993;86(6):582-9. doi: 10.1007/BF00294296. Acta Neuropathol. 1993. PMID: 7906072
-
Cell proliferation in colorectal adenocarcinomas: comparison between Ki-67 immunostaining and bromodeoxyuridine uptake detected by immunohistochemistry and flow cytometry.Pathol Res Pract. 2001;197(6):411-8. doi: 10.1078/0344-0338-00054. Pathol Res Pract. 2001. PMID: 11432668
-
Methodological aspects of using immunohistochemical cell proliferation biomarkers in colorectal carcinoma chemoprevention.J Cell Biochem Suppl. 1994;19:61-7. J Cell Biochem Suppl. 1994. PMID: 7823607 Review.
-
Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers.Anal Cell Pathol. 1998;16(1):45-62. doi: 10.1155/1998/545906. Anal Cell Pathol. 1998. PMID: 9584899 Free PMC article. Review.
Cited by
-
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).Pathol Oncol Res. 1996;2(3):191-211. doi: 10.1007/BF02903527. Pathol Oncol Res. 1996. PMID: 11173606
-
Ki-67 expression in early prostate cancer and associated pathological lesions.J Clin Pathol. 1996 Sep;49(9):741-8. doi: 10.1136/jcp.49.9.741. J Clin Pathol. 1996. PMID: 9038759 Free PMC article.
-
The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer.Cancer Res Treat. 2019 Oct;51(4):1411-1419. doi: 10.4143/crt.2018.663. Epub 2019 Feb 25. Cancer Res Treat. 2019. PMID: 30913874 Free PMC article.
-
Overexpression of SMARCA5 correlates with cell proliferation and migration in breast cancer.Tumour Biol. 2015 Mar;36(3):1895-902. doi: 10.1007/s13277-014-2791-2. Epub 2014 Nov 7. Tumour Biol. 2015. PMID: 25377162
-
Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment.Pathol Oncol Res. 1996;2(4):276-292. doi: 10.1007/BF02904824. Pathol Oncol Res. 1996. PMID: 11173616
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous